Cargando…
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial
BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206242/ https://www.ncbi.nlm.nih.gov/pubmed/35717166 http://dx.doi.org/10.1186/s12885-022-09758-z |
_version_ | 1784729297533009920 |
---|---|
author | van Heek, Lutz Stuka, Colin Kaul, Helen Müller, Horst Mettler, Jasmin Hitz, Felicitas Baues, Christian Fuchs, Michael Borchmann, Peter Engert, Andreas Dietlein, Markus Voltin, Conrad-Amadeus Kobe, Carsten |
author_facet | van Heek, Lutz Stuka, Colin Kaul, Helen Müller, Horst Mettler, Jasmin Hitz, Felicitas Baues, Christian Fuchs, Michael Borchmann, Peter Engert, Andreas Dietlein, Markus Voltin, Conrad-Amadeus Kobe, Carsten |
author_sort | van Heek, Lutz |
collection | PubMed |
description | BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial. METHODS: (18)F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV(4.0,) SUV(41%) and SUV(140%L)), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy. RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV(4.0) for MTV- calculation (AUC 0.69 [95% CI 0.55–0.83]) and for TLG-calculation (AUC 0.69 [0.55–0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV(140%L) AUCs of 0.66 [0.53–0.80] for MTV and 0.67 for TLG [0.54–0.81]) were observed, while with SUV(41%) an AUC of 0.61 [0.45–0.76] for MTV, and an AUC 0.64 [0.49–0.80]) for TLG were seen. CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV(4.0) for MTV and TLG calculation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00736320. |
format | Online Article Text |
id | pubmed-9206242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-92062422022-06-19 Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial van Heek, Lutz Stuka, Colin Kaul, Helen Müller, Horst Mettler, Jasmin Hitz, Felicitas Baues, Christian Fuchs, Michael Borchmann, Peter Engert, Andreas Dietlein, Markus Voltin, Conrad-Amadeus Kobe, Carsten BMC Cancer Research Article BACKGROUND: (18)F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial. METHODS: (18)F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV(4.0,) SUV(41%) and SUV(140%L)), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy. RESULTS: All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV(4.0) for MTV- calculation (AUC 0.69 [95% CI 0.55–0.83]) and for TLG-calculation (AUC 0.69 [0.55–0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV(140%L) AUCs of 0.66 [0.53–0.80] for MTV and 0.67 for TLG [0.54–0.81]) were observed, while with SUV(41%) an AUC of 0.61 [0.45–0.76] for MTV, and an AUC 0.64 [0.49–0.80]) for TLG were seen. CONCLUSIONS: MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV(4.0) for MTV and TLG calculation. TRIAL REGISTRATION: ClinicalTrials.gov NCT00736320. BioMed Central 2022-06-18 /pmc/articles/PMC9206242/ /pubmed/35717166 http://dx.doi.org/10.1186/s12885-022-09758-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article van Heek, Lutz Stuka, Colin Kaul, Helen Müller, Horst Mettler, Jasmin Hitz, Felicitas Baues, Christian Fuchs, Michael Borchmann, Peter Engert, Andreas Dietlein, Markus Voltin, Conrad-Amadeus Kobe, Carsten Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title | Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title_full | Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title_fullStr | Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title_full_unstemmed | Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title_short | Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial |
title_sort | predictive value of baseline metabolic tumor volume in early-stage favorable hodgkin lymphoma – data from the prospective, multicenter phase iii hd16 trial |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206242/ https://www.ncbi.nlm.nih.gov/pubmed/35717166 http://dx.doi.org/10.1186/s12885-022-09758-z |
work_keys_str_mv | AT vanheeklutz predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT stukacolin predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT kaulhelen predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT mullerhorst predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT mettlerjasmin predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT hitzfelicitas predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT baueschristian predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT fuchsmichael predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT borchmannpeter predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT engertandreas predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT dietleinmarkus predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT voltinconradamadeus predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial AT kobecarsten predictivevalueofbaselinemetabolictumorvolumeinearlystagefavorablehodgkinlymphomadatafromtheprospectivemulticenterphaseiiihd16trial |